论文部分内容阅读
目的：明确BRafV600E/ERK通路与单极纺锤体蛋白激酶1（Mps1）在乳腺癌发生发展中的相关性。方法采用免疫组织化学技术检测60例乳腺癌、20例乳腺良性疾病Mps1蛋白以及p-ERK的表达情况。结果 Mps1蛋白在乳腺癌中阳性表达率为77％（46/60）明显高于乳腺良性疾病10％（2/20）（P＜0．01），p-ERK在乳腺癌中阳性表达率为83％（50/60）明显高于乳腺良性疾病33％（5/15）（P＜0．01），p-ERK表达阳性的病例同时显示Mps1阳性表达，反之亦然。二者在乳腺癌中显著相关（R2＝0．367，P＜0．05）。且Mps1蛋白的表达与年龄无关（P＞0．05），而在有淋巴结转移乳腺癌中的表达水平高于无淋巴结转移（P＜0．05），在Ⅲ＋Ⅳ期的表达水平高于Ⅰ＋Ⅱ期（P＜0．05）。结论 Mps1与BRafV600E/ERK通路在乳腺癌发生发展中呈正相关，且Mps1蛋白表达与有无淋巴结转移、TNM临床分期密切相关。“,”Objective To determine the correlation between Mps1 and BRaf V600E/ERK pathway in breast cancer. Methods The correlation between Mps1 and p-ERK was evaluated by using immunohistochemistry in 60 patients with breast cancer and 20 with benign breast diseases. Results The positivity of Mps1 [(77% (46/60) vs.10% (2/20), P<0.01] and p-ERK [33%(5/15) vs. 83%(50/60), P<0.01] in breast cancer was significantly higher than that in breast benign diseases. The samples with p-ERK immunostaining positive also showed immunoreactivity of Mps1, and the vice versa, suggesting that Mps1 expression was positively correlated with p-ERK in breast cancer (R2=0.367, P0.05). The level of Mps1 expression was higher in patients with lymph node metastasis than those without, and higher in phase Ⅲ+Ⅳ breast cancer than in phaseⅠ+Ⅱ breast cancer (both P<0.05). Conclusion The Mps1 correlates with the activity of BRaf V600E signaling in breast cancer and is closely associated with lymph node metastasis and clinical stage of TNM.